Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer

A cancer stem cell and ganglioside technology, applied in chemical instruments and methods, anti-receptor/cell surface antigen/cell surface determinant immunoglobulin, antibody medical components, etc.

Pending Publication Date: 2016-02-17
OGD2 PHARMA +1
View PDF6 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Unfortunately, most known CSC markers are also expressed in normal tissues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
  • Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer
  • Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for cancer stem cells cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0201] Next, the present invention will be described in more detail with reference to amino acid sequence, nucleic acid sequence and Examples. However, the details of the examples are not intended to limit the invention. Rather, the invention applies to any embodiment that includes details not explicitly mentioned in the examples herein, but which can be discovered by those skilled in the art without undue effort.

[0202] · Glioma

[0203] Evaluation of OAcGD2 Ganglioside Expression in Glioma

[0204] o OAcGD2 Expression in Glioblastoma Biopsies

[0205] The inventors assessed the expression of O-acetylated GD2 ganglioside (OAcGD2) in 22 glioblastoma samples using immunohistochemistry (IHC). figure 1 An example of immunohistochemical staining for diagnosis is shown in , where tissue was stained for the OAcGD2 antigen.

[0206] Samples of the tumor (glioblastoma) were obtained from surgical sections. Remove tissue samples (volume ≤ 0.5cm 3 ) and frozen in isopentan...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates to an antibody recognizing the O-acetylated-GD2 ganglioside for the treatment of Cancer Stem Cells (CSC) cancer. The present disclosure further concern a pharmaceutical composition comprising said antibody for treating a CSC cancer and a method for treating a CSC cancer in a patient in need thereof, said method comprising administering said antibody to said patient. The present disclosure also relates to a method for diagnosing a CSC and to the use of the 0-acetylated-GD2 ganglioside as a biomarker of CSC cancer. Finally, the disclosure relates to a method for predicting the response of a subject affected with CSC cancer to a treatment with an antibody or a composition of the invention.

Description

[0001] This International Patent Application claims priority from European Patent Application 13002268.4 filed on April 29, 2014, which is hereby incorporated by reference. technical field [0002] The present invention relates to antibodies, pharmaceutical compositions and methods for the treatment and / or diagnosis of cancer stem cell (CSC) cancer. Background technique [0003] cancer stem cells [0004] Advances in medical research in recent decades have resulted in important improvements in existing cancer treatment strategies. While conventional treatment strategies including chemotherapy, radiotherapy, hormone therapy and surgery continue to be researched and applied, new methods of cancer control, often referred to as "targeted cancer therapy", are emerging and demonstrating their effectiveness in the medical field and benefits. These targeted therapies include monoclonal antibodies against tumor antigens, such as trastuzumab (anti-Her2Neu), rituximab (anti-CD20) or ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/30
CPCA61K2039/505A61P35/00A61P35/02A61P35/04A61P43/00C07K16/3084C07K2317/73A61K39/39558A61K45/06A61N5/10C07K2317/24C07K2317/622C07K2317/626
Inventor 斯蒂芬·比尔克莱丹尼斯·科绍诺米莱内·多维柳斯让-马可·勒·杜萨尔米奇卡尔·泰姆
Owner OGD2 PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap